Trial Endpoints and Safety Assessments The primary endpoint was area under the semaglutide plasma concentration-time curve over a dosing interval at steady state (AUC 0168 h,SS ) after the last administration of OW s.c
For injectable formulations, storage requirements differ by product
You can download the full pricing chart here
Melnyk S, Fuchs GJ, Schulz E, Lopez M, Kahler SG, Fussell JJ et al
In laboratory settings, the Glucagon component has been noted to elevate heart rate in subjects more significantly than standard GLP-1 agonists.
Class research on GLP-1 receptor agonists suggests reduced interest in drinking for some people, and possible liver-related benefits but that is not a green light to drink through nausea or empty calories